Intelligent Bio Solutions (INBS) Cash & Equivalents (2020 - 2025)

Intelligent Bio Solutions has reported Cash & Equivalents for 6 years, with the latest figure at $1.0 million in Q2 2025.

• For the quarter ending Q2 2025, Cash & Equivalents changed N/A year-over-year to $1.0 million; the trailing twelve-month figure through Jun 2025 stood at $1.0 million (changed N/A YoY), and the FY2025 full-year result was $1.0 million, changed N/A from the prior year.
• Cash & Equivalents for Q2 2025 stood at $1.0 million, down from $2.8 million in the prior quarter.
• The five-year high for Cash & Equivalents was $14.3 million in Q1 2021, with the low at $1.0 million in Q2 2025.
• Average Cash & Equivalents over 5 years is $6.6 million, with a median of $4.9 million recorded in 2022.
• Year-over-year, Cash & Equivalents jumped 2842.78% in 2021 and tumbled 78.8% in 2023.
• Tracing INBS's Cash & Equivalents over 5 years: stood at $11.2 million in 2021, then slumped by 73.98% to $2.9 million in 2022, then sank by 61.57% to $1.1 million in 2023, then soared by 100.18% to $2.2 million in 2024, then slumped by 54.47% to $1.0 million in 2025.
• The last three Cash & Equivalents figures came in at $1.0 million (Q2 2025), $2.8 million (Q1 2025), and $2.2 million (Q4 2024), per Business Quant data.

Peer Comparison